Articles tagged with Drug Development
Research reveals that teenagers' brains respond differently to drugs than adults, with greater cognitive shortfalls and altered stress responses. Long-term effects of adolescent drug use on brain chemistry are also being explored.
Researchers have successfully delivered a protective protein called erythropoietin into the brain using a Trojan Horse approach, overcoming the blood-brain barrier's ability to block it. This breakthrough has potential for treating stroke patients, traumatic head injuries, Parkinson's disease, and other chronic brain disorders.
The use of graphics processing units (GPUs) is accelerating the simulation of molecule movement, reducing processing times from years to months for the development of new drugs. Chemists are embracing this technology to streamline computations and accelerate discovery.
Human African Trypanosomiasis, also known as sleeping sickness, affects millions in Africa and South America. Researchers at the University of Strathclyde are developing a new oral treatment to tackle the disease.
A meta-analysis of nine studies found that patients with common genetic variants of the CYP2C19 gene and taking clopidogrel for cardiac procedures are at increased risk of major adverse cardiovascular events, including blood clots in stents. The study suggests that individualized treatment regimens may be needed to tailor therapy.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded four new contracts for large-scale clinical trials to evaluate treatment alternatives for diseases caused by resistant bacteria. These trials will focus on acute otitis media, community-acquired pneumonia, and Gram-negative bacterial infections.
Robert Langer will receive the Founders Award for his contributions to drug delivery and tissue engineering, while Anita Jones will receive the Arthur M. Bueche Award for leadership in science and technology policy. The awards recognize outstanding achievements that have benefited society.
A recent study published in Neurology found that intravenous treatment with dexamethasone can significantly reduce the mortality rate of patients with bacterial meningitis. The study revealed a 10% lower death rate among those treated with dexamethasone, highlighting its potential as an effective therapeutic option.
Scientists at Rensselaer Polytechnic Institute used nuclear magnetic resonance (NMR) to understand and improve an important protein purification process. The study validated the effectiveness of multimodal chromatography, a method that separates proteins from their surrounding materials using molecular glue.
Scientists have identified a potential new treatment for toxoplasmosis, an infection affecting almost 2 billion people worldwide. Triclosan, commonly found in soaps and toothpastes, has shown promise as a guiding light for developing effective medications.
A large clinical study found patients with specific genetic variations in the IL-1Ra gene were almost twice as likely to progress to severe osteoarthritis. The study suggests using genetic patterns to identify high-risk patients for clinical trials and personalize treatment plans.
New findings from a major drug trial have revealed that the platelet function in patients taking ticagrelor recovered much quicker after the drug is stopped, compared to clopidogrel. Additionally, ticagrelor has been shown to prevent 1 in 5 deaths after a heart attack, even in patients with adverse effects like breathlessness.
A team led by Dr. Jonathan Stamler will research the development of a new class of drugs that selectively dilate blood cells under hypoxia, enhancing soldiers' performance at high altitudes. The grant aims to improve tissue oxygenation and deliver more oxygen to tissues despite low blood oxygen content.
The new fluorescent biosensor could aid in the development of drugs targeting GPCRs, a crucial class of proteins present in cells. The biosensor uses fluoromodules to monitor protein activity and provides a homogeneous assay that can screen large numbers of molecules to identify new drug leads.
A study found that drugs inhibiting the protein MTOR can impair heart function in patients with ongoing heart dysfunction. Additionally, researchers discovered that deleting the protein 4E-BP1 improved heart function and survival in mice. These findings suggest a potential new therapeutic strategy for improving heart health.
Scientists discover A20 protein plays a protective role in chronic bowel inflammation, making it a promising therapeutic target. The study confirms genome-wide analysis results showing defects in A20 associated with Crohn's disease development.
The African Network for Drugs and Diagnostics Innovation aims to stimulate health product research and development in Africa. Successful implementation requires sustainable capacity, infrastructure, funding, leadership, and understanding of health R&D in the African continent.
Experts argue for shifting focus from biomedical mechanisms to socio-environmental aspects of neglected tropical diseases. Mass drug administration is recognized as a cost-effective approach for controlling these diseases, while integrating biomedical and social approaches through 'social offsets' may complement this strategy.
Scientists at the University of Gothenburg have created a method to develop safer drugs by simulating metabolism and identifying potentially toxic metabolites. This approach has been successfully applied to the antimalarial drug amodiaquine, which was withdrawn due to liver damage and immune system impairment.
Dental providers can prepare for medical emergencies by stocking essential medications and equipment, such as automated external defibrillators and portable oxygen delivery systems. The new guidelines provide a detailed list of emergency medications and equipment to ensure timely and effective treatment.
Telcagepant, a CGRP receptor blocker, provides similar pain relief as triptans but with fewer cardiovascular risks. Topiramate may also prevent migraine attacks in chronic sufferers.
Researchers at the University of Leeds have discovered how two proteins manipulate nerve cells to send pain signals, offering a new target for painkillers. This breakthrough could lead to more effective and safer pain treatments by targeting peripheral nervous system.
A new combination drug treatment has been found to be effective in controlling parasitic worms, reducing the need for repeated treatments and minimizing drug resistance. The dual therapy uses a protein crystal made by bacteria, which works by a different mechanism than existing levamisole-like drugs.
Researchers at Duke University Medical Center and the University of Oxford conducted a study to find ways to control progression to diabetes and cardiovascular disease in people at risk. Valsartan showed a moderate effect on reducing diabetes progression, but nateglinide proved ineffective at halting this progression.
Researchers have discovered a Bt protein that is highly effective at curing intestinal parasitic roundworm infections in humans. The Cry5B protein produced by the Bt bacterium is three times better than tribendimidine and shows promise as an alternative to existing treatments.
A Tel Aviv University study suggests that early intervention may be able to prevent schizophrenia in those at high risk. The researchers found that administering drugs to rats during adolescence prevented the development of schizophrenia-like symptoms and brain deterioration.
Researchers found a 'longevity gene' associated with slower cognitive decline and reduced risk of dementia and Alzheimer's disease. The CETP gene variant alters protein function, leading to higher HDL cholesterol levels and increased protection against age-related illnesses.
Researchers propose integrating NTD interventions into the regular health system, leveraging resources from malaria, HIV/AIDS, and tuberculosis programs. Careful planning and community engagement are crucial for successful integration and co-implementation of these efforts.
Researchers have developed a new survival prediction equation for pulmonary arterial hypertension (PAH), improving upon an outdated NIH equation. The new formula shows vastly improved survival rates, highlighting the need for accurate hemodynamic assessment.
Researchers at Gladstone Institute of Neurological Disease have discovered that two main causes of AD, amyloid-beta peptides and apolipoprotein E4, impair the growth of new neurons born in adult brains. Drug treatments can normalize their development even in the presence of these factors.
A global drive is necessary to develop new antibiotics, with only a single new antibacterial approved in the USA since 2006. The EU report also shows limited progress, with just five new drugs reaching phase 3 clinical trials within the next 10 years.
Scientists have observed ion channels within the surface membrane of cells for the first time, improving our understanding of how signals travel among neurons. This discovery may lead to a complete picture of how ion channels function and could have implications for future drug development.
Researchers have found a way to control male fertility using testicular hormone levels, offering hope for those with low sperm counts. The discovery provides a promising avenue for developing new treatments for male infertility and potentially new male contraceptives.
A study published in PLOS Medicine found that dementia is often associated with mixed pathological changes, including Alzheimer's and vascular dementia. The researchers estimated that drugs targeting specific pathologies may have limited impact on the overall burden of dementia.
A study by Pitt researchers found that a free-radical scavenger, JP4-039, accelerated bone fracture healing in mice treated with the drug after radiation exposure. This could have significant implications for pediatric cancer patients vulnerable to late effects of radiation on bone growth and development.
The Canadian Cardiovascular Society recognizes Dr. Gavin Y. Oudit's groundbreaking research on a new class of drugs for treating heart failure, with the potential to also treat kidney and lung diseases. Oudit's innovative program has yielded major discoveries and established him as a world leader in this exciting area of research.
Researchers found that antiepileptic drugs administered during brain development increase schizophrenia-like behaviors in animal models. In humans, having a history of seizures is a significant risk factor for developing schizophrenia.
Researchers at the University of Manchester discovered two types of brain cells with distinct electrical properties that differ significantly between day and night. One type contains a key gene and can survive high levels of excitability, while the other cannot, contradicting accepted theory on how the daily clock works.
Scientists have developed micrometer-sized capsules that can safely deliver drugs inside living cells. These 'micro shuttles' can be loaded with specific doses and released by biological triggers or light activation, offering a promising solution for managing chronic conditions.
Researchers in the UK create a surface with hydrophobic and hydrophilic sections to move plastic nanoparticles quickly and in specific directions. This breakthrough could lead to advancements in treating diseases by coaxing cells to grow and heal in desired ways.
Researchers at Michigan Medicine have developed a combination drug that regulates the release of morphine and its antagonist, improving pain management for patients with chronic illnesses. The nanoparticle-based system uses a pro drug to sense oxygen levels and trigger the release of Naloxone, allowing for safer treatment in combat zones.
A Purdue University researcher developed a fiber-optic sensor capable of measuring oxygen intake rates in real-time. The self-referencing optrode has broad applications across disciplines, including biomedical science, agriculture, and material science.
A new study found that Canadian health biotech firms collaborating with developing countries have a strong interest in building partnerships, driven by access to emerging markets and cost savings. Joint R&D activities are nearly as common as distribution arrangements, reflecting bi-directional knowledge-intensive collaboration.
Researchers at the University of Michigan have identified a gene called IKKE that acts as a master switch to control obesity in mice. Deleting this gene also appears to protect mice against conditions associated with Type 2 diabetes and obesity.
Researchers at Instituto Gulbenkian de Ciencia discover that an enzyme called heme oxygenase-1 (HO-1) protects mice from developing severe forms of malaria. An anti-oxidant drug, N-acetylcysteine (NAC), has the same effect on Plasmodium-infected mice.
A large multicentre study has confirmed that a combination of proteins in the cerebrospinal fluid can reliably identify patients with early symptoms of dementia who will later develop full-blown Alzheimer's disease. The findings may lead to new medicines and point-of-care diagnostics.
Researchers have discovered a key link between protein CCKR2 and progastrin-related colonic hyperproliferation. Deletion of the Cck2r gene in mice with human progastrin overexpression abolished colonic hyperproliferation and reduced colorectal cancer, suggesting CCKR2 as a viable target for treatment.
New vaccines, drug regimens, and diagnostics under development have the potential to significantly impact tuberculosis. The study predicts a 39-52% decrease in TB incidence through vaccination, while new drug regimens could reduce incidence by 10-27%. Diagnostic tools may also contribute to improved outcomes.
Eliminating polio requires global cooperation on lowering vaccine costs and strengthening surveillance. Experts argue that coordinated efforts are necessary to succeed in eradicating the disease.
A clinical trial of masitinib has shown it to be well-tolerated and effective in reducing the severity of active rheumatoid arthritis. The treatment was found to significantly reduce inflammation and improve symptoms, with mild to moderate side effects.
Noroviruses cause the greatest incidence of vomiting and diarrhoea globally, resulting in approximately 200,000 child deaths annually. A new study suggests that targeting sugar chains with sialic acid could prevent virus attachment to cells.
RGI-2001 demonstrates enhanced efficacy in skin transplantation and acute Graft-versus-Host disease when combined with low-dose Sirolimus. The combination treatment prolongs graft survival and reduces GvHD mortality, indicating potential as a tolerance induction regimen.
Researchers at Northwestern University have developed a Nanofountain Probe that can precisely deliver tiny doses of drug-carrying nanomaterials to individual cells. The tool enables targeted cancer treatments and improves drug delivery by reducing side effects and increasing targeting accuracy.
Researchers developed a mathematical model predicting optimal time for loading and unloading cryoprotectants, which reduces egg size shifts and improves fertilization chances. Using sugars like trehalose, these staged drugs can help preserve eggs at subzero temperatures, enabling easier transportation and potential transplantation.
A developmental drug, JP4-039, has been shown to protect cells from radiation-induced cell death by assisting the mitochondria in combating irradiation. The study suggests a potential role for the drug as a mitigator of radiation damage.
International experts propose MEDQUARG guidelines to study counterfeit and poor-quality medicines globally. The guidelines aim to improve the effectiveness of treatment policies by providing a standard for medicine quality surveys.
A study by the University of Edinburgh found a gene called DISC1 may control how patients respond to psychiatric medication, offering a potential breakthrough in treating mental illnesses. The research identified seven proteins important to mental illness development, aiming to create new medicines targeting these proteins.
Researchers at the University of Innsbruck have discovered that BASP1 inhibits uncontrolled cell growth and proliferation caused by the Myc gene, which is a key factor in tumor development.
A study published in JAMA found that dexmedetomidine reduced delirium prevalence and improved extubation times compared to midazolam, a commonly used sedative drug. The medication also showed a lower risk of bradycardia but higher tachycardia rates.
Researchers have developed a new approach for treating pneumococci by emulating the choline architecture of their cell walls. This method traps critical pneumococcal proteins, preventing bacterial growth and toxin release. The resulting CBP inhibitor has a suitable dosage range for pharmaceuticals.